Assessment of the Role of Tegaserod Therapy in the Management of Gastroesophageal Reflux Disease (GERD) Symptoms in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).

Inclusion Criteria: * Heartburn for at least 3 days in the week prior to screening * Regurgitation for at least 3 days in the week prior to screening * Stable dose PPI therapy \> 4 weeks * Incomplete relief on daily PPI therapy \> 4 weeks Exclusion Criteria: * Evidence of structural abnormality of the gastrointestinal tract or disease/conditions * Previous gastrointestinal surgery that may influence esophageal motor function * Evidence of cathartic colon or a history of laxative use Other protocol-defined inclusion/exclusion criteria may apply.